Roche HPV Test Cleared by FDA | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Roche announced today the clearance of its cobas HPV test by the US Food and Drug Administration.

The test, the company said, identifies women who are at greatest risk for developing cervical cancer, and is the only cervical cancer screening test approved by the FDA that allows HPV 16 and 18 genotyping concurrently with high-risk HPV testing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.